Inovio Forced To Delay Planned Phase 2/3 Testing Of Covid-19 Vaccine; Stock Plummets

Inovio Pharmaceuticals (INO) announced early Monday that regulators forced it to hold off on the start of its planned Phase 2/3 testing of its Covid-19 vaccine candidate, sending INO stock crashing early.